{"id":398520,"date":"2020-12-11T19:00:35","date_gmt":"2020-12-12T00:00:35","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=398520"},"modified":"2020-12-11T19:00:35","modified_gmt":"2020-12-12T00:00:35","slug":"ziopharm-comments-on-delay-of-watermills-stated-consent-deadline","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/ziopharm-comments-on-delay-of-watermills-stated-consent-deadline\/","title":{"rendered":"Ziopharm Comments on Delay of WaterMill\u2019s Stated Consent Deadline"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"center\">\n        <em>Ziopharm Recommends Shareholders Return the <\/em><br \/>\n        <strong><br \/>\n          <em><br \/>\n            <u>GREEN<\/u><br \/>\n          <\/em><br \/>\n        <\/strong><br \/>\n        <em> Consent Revocation Card<\/em><br \/>\n        \n      <\/p>\n<p align=\"justify\">BOSTON, Dec.  11, 2020  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=fP3f7-SG9lEvmL5yZMl9jT_QAACvaH5F_spDtD82Y8Eke8EdD4Ghw9soRpYCvw_bDAtycvm6v8qzX8WfTb6NgA==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">Ziopharm Oncology<\/a>, Inc. (Nasdaq: ZIOP) (\u201cZiopharm\u201d or the \u201cCompany\u201d), today issued a statement in connection with the consent solicitation (the \u201cConsent Solicitation\u201d) initiated by WaterMill Asset Management Corp., Mr. Robert W. Postma and certain other individuals (collectively, \u201cWaterMill\u201d) following the delay of the original December 11 deadline set by WaterMill for Ziopharm shareholders to deliver written consents in support of the Consent Solicitation. Ziopharm continues to strongly recommend shareholders sign and return the Company\u2019s <strong><u>GREEN<\/u><\/strong> Consent Revocation Card.<\/p>\n<p align=\"justify\">The statement is as follows:<\/p>\n<p align=\"justify\">\n        <em>\u201cWe have been informed that WaterMill has requested to delay the voting deadline until December 15, a clear sign that it does not appear to have the level of shareholder support for its proposals it claimed to have. As has been the case since this process commenced in mid-October, Ziopharm\u2019s Board and management team remain fully committed to acting in the best interest of shareholders and have relayed the Company\u2019s willingness to reach an amicable resolution with WaterMill. It is our preference to resolve this matter amicably so we can continue to focus on our important progress toward developing therapies that could treat the millions of people globally diagnosed with a solid tumor each year.\u201d<\/em>\n      <\/p>\n<p align=\"justify\">Information related to the Consent Solicitation can be found at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=4kZ1xhbB_mgZxt457j1Tl3TF4EI_x5ZTOXIGEboWeNuCvbbKt4QRSQte4XVXv7VtmC6EgNWA3pw3tGXwdevR1kNDGOeH-ETGZ3iTNhNH4I8=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">www.ZiopharmForward.com<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>About Ziopharm Oncology, Inc.<\/strong><br \/>\n        <br \/>Ziopharm is developing non-viral and cytokine-driven cell and gene therapies that weaponize the body\u2019s immune system to treat the millions of people globally diagnosed with a solid tumor each year. With its multiplatform approach, Ziopharm is at the forefront of immuno-oncology with a goal to treat any type of solid tumor. Ziopharm\u2019s pipeline is built for commercially scalable, cost effective T-cell receptor T-cell therapies based on its non-viral Sleeping Beauty gene transfer platform, a precisely controlled IL-12 gene therapy, and rapidly manufactured Sleeping Beauty-enabled CD19-specific CAR-T program. The Company has clinical and strategic partnerships with the National Cancer Institute, The University of Texas MD Anderson Cancer Center and others. For more information, please visit www.ziopharm.com.<\/p>\n<p align=\"justify\">\n        <strong>Forward-Looking Statements <\/strong><br \/>\n        <br \/>This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements regarding the business strategy, plans and objectives of Ziopharm management and expectations as to and beliefs about the Consent Solicitation initiated by WaterMill. Forward-looking statements include all statements that are not historical facts, and can be identified by terms such as \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccontemplate,\u201d \u201ccontinue,\u201d \u201ccould,\u201d \u201cestimate,\u201d \u201cexpect,\u201d \u201chope,\u201d \u201cintend,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201cobjective,\u201d \u201congoing,\u201d \u201cplan,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cshould,\u201d \u201ctarget,\u201d \u201cwill,\u201d or \u201cwould\u201d or similar expressions and the negatives of those terms. Any forward-looking statements are based on management\u2019s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. Such risks and uncertainties include, among others, the impact and results of the Consent Solicitation and other activities by WaterMill and\/or other investors, the risks and uncertainties disclosed in Ziopharm\u2019s most recent Quarterly Report on Form 10-Q for the quarter ended September 30, 2020 as well as discussions of potential risks, uncertainties and other important factors in any subsequent filings by Ziopharm with the Securities and Exchange Commission (the \u201cSEC\u201d). All information in this press release is as of the date hereof, and Ziopharm undertakes no duty to update the information, except as required by law.<\/p>\n<p align=\"justify\">\n        <strong>Important Additional Information and Where to Find It<\/strong><br \/>\n        <br \/>Ziopharm has filed a definitive consent revocation statement (the \u201cConsent Revocation Statement\u201d) together with a <strong><u>GREEN<\/u><\/strong> consent revocation card with the SEC in connection with the Consent Solicitation. SHAREHOLDERS ARE URGED TO READ THE CONSENT REVOCATION STATEMENT (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO) AND ANY OTHER RELEVANT DOCUMENTS THAT ZIOPHARM FILES WITH THE SEC CAREFULLY IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. Shareholders will be able to obtain, free of charge, copies of the Consent Revocation Statement (including the <strong><u>GREEN<\/u><\/strong> consent revocation card), any amendments or supplements thereto and any other documents that Ziopharm files with the SEC from the SEC\u2019s website (<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=zK5wexFnrHaY_GIKohCq8h_wx1WzfTiMDBCMap05p0oJJ0OO2DhLRnnBwNqblUDicdNvuKi8KoutWyU6Q2QZDw==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">http:\/\/www.sec.gov<\/a>) or from Ziopharm\u2019s website (<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=EtfysalJWPw1OttTqFrldkxRiXj6gdkH5O5swqSNz44d4_6eg9Er6urgAPwwGYyCkWuij2UO3NZevyMi7fBK6w==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">www.ziopharm.com<\/a>) by clicking on \u201cInvestors\u201d and then \u201cSEC Filings.\u201d<\/p>\n<p align=\"justify\">\n        <strong>Investor Relations Contacts:<\/strong><br \/>\n        <br \/>Adam D. Levy, PhD, MBA<br \/>EVP, Investor Relations and Corporate Communications<br \/>(508) 552-9255<br \/>alevy@ziopharm.com<\/p>\n<p align=\"justify\">Michael Verrechia<br \/>Morrow Sodali<br \/>(212) 300-2476<br \/>m.verrechia@morrowsodali.com<\/p>\n<p align=\"justify\">\n        <strong>Media Relations Contacts:<\/strong><br \/>\n        <br \/>Chris Kittredge, Andrew Cole and Zachary Tramonti<br \/>Sard Verbinnen &amp; Co.<br \/>Ziopharm-SVC@sardverb.com<\/p>\n<p>\u00a0<\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEwMTE3NiMzODY4NTU2IzIwMDc1NTA=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/5bf4a641-314b-4497-9344-84302759bb75\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Ziopharm Recommends Shareholders Return the GREEN Consent Revocation Card BOSTON, Dec. 11, 2020 (GLOBE NEWSWIRE) &#8212; Ziopharm Oncology, Inc. (Nasdaq: ZIOP) (\u201cZiopharm\u201d or the \u201cCompany\u201d), today issued a statement in connection with the consent solicitation (the \u201cConsent Solicitation\u201d) initiated by WaterMill Asset Management Corp., Mr. Robert W. Postma and certain other individuals (collectively, \u201cWaterMill\u201d) following the delay of the original December 11 deadline set by WaterMill for Ziopharm shareholders to deliver written consents in support of the Consent Solicitation. Ziopharm continues to strongly recommend shareholders sign and return the Company\u2019s GREEN Consent Revocation Card. The statement is as follows: \u201cWe have been informed that WaterMill has requested to delay the voting deadline until December 15, a clear sign that it &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/ziopharm-comments-on-delay-of-watermills-stated-consent-deadline\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Ziopharm Comments on Delay of WaterMill\u2019s Stated Consent Deadline&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-398520","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Ziopharm Comments on Delay of WaterMill\u2019s Stated Consent Deadline - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/ziopharm-comments-on-delay-of-watermills-stated-consent-deadline\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ziopharm Comments on Delay of WaterMill\u2019s Stated Consent Deadline - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Ziopharm Recommends Shareholders Return the GREEN Consent Revocation Card BOSTON, Dec. 11, 2020 (GLOBE NEWSWIRE) &#8212; Ziopharm Oncology, Inc. (Nasdaq: ZIOP) (\u201cZiopharm\u201d or the \u201cCompany\u201d), today issued a statement in connection with the consent solicitation (the \u201cConsent Solicitation\u201d) initiated by WaterMill Asset Management Corp., Mr. Robert W. Postma and certain other individuals (collectively, \u201cWaterMill\u201d) following the delay of the original December 11 deadline set by WaterMill for Ziopharm shareholders to deliver written consents in support of the Consent Solicitation. Ziopharm continues to strongly recommend shareholders sign and return the Company\u2019s GREEN Consent Revocation Card. The statement is as follows: \u201cWe have been informed that WaterMill has requested to delay the voting deadline until December 15, a clear sign that it &hellip; Continue reading &quot;Ziopharm Comments on Delay of WaterMill\u2019s Stated Consent Deadline&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/ziopharm-comments-on-delay-of-watermills-stated-consent-deadline\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-12-12T00:00:35+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEwMTE3NiMzODY4NTU2IzIwMDc1NTA=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ziopharm-comments-on-delay-of-watermills-stated-consent-deadline\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ziopharm-comments-on-delay-of-watermills-stated-consent-deadline\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Ziopharm Comments on Delay of WaterMill\u2019s Stated Consent Deadline\",\"datePublished\":\"2020-12-12T00:00:35+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ziopharm-comments-on-delay-of-watermills-stated-consent-deadline\\\/\"},\"wordCount\":777,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ziopharm-comments-on-delay-of-watermills-stated-consent-deadline\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEwMTE3NiMzODY4NTU2IzIwMDc1NTA=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ziopharm-comments-on-delay-of-watermills-stated-consent-deadline\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ziopharm-comments-on-delay-of-watermills-stated-consent-deadline\\\/\",\"name\":\"Ziopharm Comments on Delay of WaterMill\u2019s Stated Consent Deadline - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ziopharm-comments-on-delay-of-watermills-stated-consent-deadline\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ziopharm-comments-on-delay-of-watermills-stated-consent-deadline\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEwMTE3NiMzODY4NTU2IzIwMDc1NTA=\",\"datePublished\":\"2020-12-12T00:00:35+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ziopharm-comments-on-delay-of-watermills-stated-consent-deadline\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ziopharm-comments-on-delay-of-watermills-stated-consent-deadline\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ziopharm-comments-on-delay-of-watermills-stated-consent-deadline\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEwMTE3NiMzODY4NTU2IzIwMDc1NTA=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEwMTE3NiMzODY4NTU2IzIwMDc1NTA=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ziopharm-comments-on-delay-of-watermills-stated-consent-deadline\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ziopharm Comments on Delay of WaterMill\u2019s Stated Consent Deadline\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Ziopharm Comments on Delay of WaterMill\u2019s Stated Consent Deadline - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/ziopharm-comments-on-delay-of-watermills-stated-consent-deadline\/","og_locale":"en_US","og_type":"article","og_title":"Ziopharm Comments on Delay of WaterMill\u2019s Stated Consent Deadline - Market Newsdesk","og_description":"Ziopharm Recommends Shareholders Return the GREEN Consent Revocation Card BOSTON, Dec. 11, 2020 (GLOBE NEWSWIRE) &#8212; Ziopharm Oncology, Inc. (Nasdaq: ZIOP) (\u201cZiopharm\u201d or the \u201cCompany\u201d), today issued a statement in connection with the consent solicitation (the \u201cConsent Solicitation\u201d) initiated by WaterMill Asset Management Corp., Mr. Robert W. Postma and certain other individuals (collectively, \u201cWaterMill\u201d) following the delay of the original December 11 deadline set by WaterMill for Ziopharm shareholders to deliver written consents in support of the Consent Solicitation. Ziopharm continues to strongly recommend shareholders sign and return the Company\u2019s GREEN Consent Revocation Card. The statement is as follows: \u201cWe have been informed that WaterMill has requested to delay the voting deadline until December 15, a clear sign that it &hellip; Continue reading \"Ziopharm Comments on Delay of WaterMill\u2019s Stated Consent Deadline\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/ziopharm-comments-on-delay-of-watermills-stated-consent-deadline\/","og_site_name":"Market Newsdesk","article_published_time":"2020-12-12T00:00:35+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEwMTE3NiMzODY4NTU2IzIwMDc1NTA=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ziopharm-comments-on-delay-of-watermills-stated-consent-deadline\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ziopharm-comments-on-delay-of-watermills-stated-consent-deadline\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Ziopharm Comments on Delay of WaterMill\u2019s Stated Consent Deadline","datePublished":"2020-12-12T00:00:35+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ziopharm-comments-on-delay-of-watermills-stated-consent-deadline\/"},"wordCount":777,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ziopharm-comments-on-delay-of-watermills-stated-consent-deadline\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEwMTE3NiMzODY4NTU2IzIwMDc1NTA=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ziopharm-comments-on-delay-of-watermills-stated-consent-deadline\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/ziopharm-comments-on-delay-of-watermills-stated-consent-deadline\/","name":"Ziopharm Comments on Delay of WaterMill\u2019s Stated Consent Deadline - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ziopharm-comments-on-delay-of-watermills-stated-consent-deadline\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ziopharm-comments-on-delay-of-watermills-stated-consent-deadline\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEwMTE3NiMzODY4NTU2IzIwMDc1NTA=","datePublished":"2020-12-12T00:00:35+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ziopharm-comments-on-delay-of-watermills-stated-consent-deadline\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/ziopharm-comments-on-delay-of-watermills-stated-consent-deadline\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ziopharm-comments-on-delay-of-watermills-stated-consent-deadline\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEwMTE3NiMzODY4NTU2IzIwMDc1NTA=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEwMTE3NiMzODY4NTU2IzIwMDc1NTA="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ziopharm-comments-on-delay-of-watermills-stated-consent-deadline\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Ziopharm Comments on Delay of WaterMill\u2019s Stated Consent Deadline"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/398520","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=398520"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/398520\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=398520"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=398520"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=398520"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}